Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Nov 17;365(20):1896-904.
doi: 10.1056/NEJMoa1110212. Epub 2011 Nov 1.

ADHD drugs and serious cardiovascular events in children and young adults

Affiliations

ADHD drugs and serious cardiovascular events in children and young adults

William O Cooper et al. N Engl J Med. .

Abstract

Background: Adverse-event reports from North America have raised concern that the use of drugs for attention deficit-hyperactivity disorder (ADHD) increases the risk of serious cardiovascular events.

Methods: We conducted a retrospective cohort study with automated data from four health plans (Tennessee Medicaid, Washington State Medicaid, Kaiser Permanente California, and OptumInsight Epidemiology), with 1,200,438 children and young adults between the ages of 2 and 24 years and 2,579,104 person-years of follow-up, including 373,667 person-years of current use of ADHD drugs. We identified serious cardiovascular events (sudden cardiac death, acute myocardial infarction, and stroke) from health-plan data and vital records, with end points validated by medical-record review. We estimated the relative risk of end points among current users, as compared with nonusers, with hazard ratios from Cox regression models.

Results: Cohort members had 81 serious cardiovascular events (3.1 per 100,000 person-years). Current users of ADHD drugs were not at increased risk for serious cardiovascular events (adjusted hazard ratio, 0.75; 95% confidence interval [CI], 0.31 to 1.85). Risk was not increased for any of the individual end points, or for current users as compared with former users (adjusted hazard ratio, 0.70; 95% CI, 0.29 to 1.72). Alternative analyses addressing several study assumptions also showed no significant association between the use of an ADHD drug and the risk of a study end point.

Conclusions: This large study showed no evidence that current use of an ADHD drug was associated with an increased risk of serious cardiovascular events, although the upper limit of the 95% confidence interval indicated that a doubling of the risk could not be ruled out. However, the absolute magnitude of such an increased risk would be low. (Funded by the Agency for Healthcare Research and Quality and the Food and Drug Administration.).

PubMed Disclaimer

Figures

Figure 1
Figure 1
Adjusted Rates for Serious Cardiovascular Events According to Use of ADHD Medications.* †Rates per 100,000 person-years were adjusted by multiplying the rate in the reference group by the hazard ratio for former and current users. ‡Hazard ratios were estimated with Cox regression models which included site-specific propensity score decile, site, medical conditions (serious cardiovascular disease, serious chronic illness), psychiatric conditions (major psychiatric illness, substance abuse, and antipsychotic use), utilization variables (medical hospitalization and general medical care access), age, and calendar year.

Comment in

References

    1. Centers for Disease Control and Prevention. Increasing prevalence of parent-reported attention-deficit/hyperactivity disorder among children - United States, 2003 and 2007. MMWR Morb Mortal Wkly Rep. 2010;59(44):1439–1443. - PubMed
    1. Brown RT, Amler RW, Freeman WS, et al. Treatment of attention-deficit/hyperactivity disorder: overview of the evidence. Pediatrics. 2005;115(6):e749–e757. - PubMed
    1. Buck ML. A monthly newsletter for health care professionals from the children's medical center at the University of Virginia. Pediatric Pharmacotherapy. 2002;8(3):1–4.
    1. Elia J, Ambrosini PJ, Rapoport JL. Treatment of attention-deficit-hyperactivity disorder. N Engl J Med. 1999;340(10):780–788. - PubMed
    1. Rappley MD. Clinical practice. Attention deficit-hyperactivity disorder. N Engl J Med. 2005;352(2):165–173. - PubMed

Publication types

Substances